Remove Conditions Remove Consumption Remove DEA Remove Treatment
article thumbnail

Psychedelic Users Tend to Be ‘One With Nature’ and Are More Passionate About Climate Change, Study Finds

Veriheal

Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. .

article thumbnail

5 Things to Talk About Besides Politics

CannaMD

Making matters worse, there’s only one farm in the entire country with DEA approval to cultivate marijuana for research purposes. A study by the American Medical Association found that 13% of workers experience a loss in productive time due to common pain conditions over a 2-week period. Marijuana in the Workplace. More Cannabis.

Therapy 80
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What Are Designer Drugs and How Dangerous Are They?

Veriheal

The Drug Enforcement Administration, or the DEA, explains that these types of drugs are also known as new psychoactive substances (NPS) and goes on to state that there are at least 300 known designer drugs, each of which belongs to one of the following three categories of NPS. Synthetic Phenethylamines. appeared first on Cannabis Central.

article thumbnail

Understanding the Current Legal Status of Psychedelics in the United States

Cannabis Law Report

Food and Drug Administration (FDA) approved esketamine (a component of Ketamine and sold under the brand name Spravato) for treatment-resistant depression. It would be separate from the existing medical system and subject to an entirely new state regulatory regime that would govern the production, sale, and consumption of psilocybin.

article thumbnail

Cannabis and the Environment: Seven Significant Side-Effects April 14, 2022

Cannabis Law Report

Part 180, Subparts D and E; that the pesticide be labeled as expressly for use on crops intended for human consumption; and that the pesticide’s active ingredients must be allowed by EPA for use on tobacco. pursuant to Drug Enforcement Agency (DEA) or state-level programs).

article thumbnail

Veriheal’s Innovation in Cannabis Scholarship 2020 Winners

Veriheal

Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Nishtha Tripathi. Program between St.

article thumbnail

Dentons Weekly Cannabis Update

Cannabis Law Report

DEA increases the cannabis research quota. The Drug Enforcement Administration (DEA) announced annual quotas for the manufacture of controlled substances for research purposes, providing for 7,000 pounds of cannabis to be used in scientific studies. Total consumption in metric tons ranged from a high of 77.44

Vaping 40